HIV mutation literature information.


  Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
 PMID: 18444871       2008       Clinical infectious diseases
Abstract: RESULTS: In an adjusted logistic regression, TDF treatment with nonnucleoside reverse-transcriptase inhibitors and/or didanosine was associated with the emergence of K65R, whereas the presence of any of the thymidine analogue mutations D67N, K70R, T215F, or K219E/Q was protective.


  Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
 PMID: 18547911       2008       The Journal of biological chemistry
Introduction: This region includes polymerase domain mutations M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E, which are referred to as thymidine analogue-associated mutations (TAMs).
Result: Furthermore, A360V was highly correlated with various mutations considered to be part of the TAMs cluster; for example, of the samples with A360V, 35% were associated with M41L, 21% with D67N, 30% with K70R, 17% with L210W, 42% with T215Y/F, and 17% with K219Q/E


  HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.
 PMID: 18667925       2008       Journal of acquired immune deficiency syndromes (1999)
Abstract: Although not significant, other TAMs (M41L, T215F/Y, K219Q/E) also occurred more frequently among CRF06_cpx strains as well.


  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
 PMID: 19000027       2008       AIDS research and human retroviruses
Abstract: Ninety-one percent of patients harbored resistance mutations; the most frequent NRTI mutations were M184V/I (37%), D67N (32%), T215Y/F (25%), K70R (21%), M41L (20%), K219Q/E (14%), and K65R (14%), reflecting the frequent use of lamuvidine and zidovudine.


  Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.
 PMID: 19005273       2008       AIDS (London, England)
Introduction: By contrast, the mutations M41L, D67N, K70R, L210W, T215F/Y and K219Q/E - typically referred to as thymidine analog mutations (TAMs) - augment the ability of HIV-1 RT to excise the chain-terminating NRTI-monophosphate from a prematurely terminated DNA chain.


  Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.
 PMID: 19067547       2008       Biochemistry
Result: By comparison, TAMs, which include M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E, increase the ability of HIV-1 RT to excise a chain-terminating NRTI-monophosphate (NRTI-MP) from a DNA chain.


  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
 PMID: 17417971       2007       Retrovirology
Result: The mutations most commonly observed (sometimes transiently) after the detection of K65R included K20R (3 animals), M41L (3 animals), S68G/K/N (12 animals), K70H/N/T/Q (9 animals), W88S (6 animals), Y115F (9 animals), F116W (6 animals), V118I (3 animals), I178M (6 animals), L214F (11 animals), and K219Q/R/E/N/D/H/G (7 animals) (table 1).
Table: K219E


  HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
 PMID: 17500586       2007       PLoS computational biology
Abstract: Different patterns of covariation were frequently observed for different mutations at the same position including the RT mutations T69D versus T69N, L74V versus
Result: K219Q/E were Type II TAMs that cluster with other Type II TAMs.
Result: The mutations included in this analysis were the 23 positively associated mutations in Table 2 and 11 additional clinically relevant NRTI-resistance mutations (K65R, A62V, T69ins, L74I/V, V75M, Y115F, M184V, and K219R/E/N).


  Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
 PMID: 17516531       2007       Journal of medical virology
Abstract: In 7 of 12 children, M184V appeared with one thymidine-analogue-associated mutation (TAM) as the first mutation, while the remaining 5 children had only TAMs appearing either individually (n = 2), or as TAMs 1 (M41L, L210W, and T215Y) and 2 (D67N, K70R, and K219Q/E/R) appearing together (n = 3).


  Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
 PMID: 17591023       2007       Antiviral therapy
Abstract: Reversion of K70G --> R and K219R --> E in a patient-derived clone confirmed the contribution of individual mutations and the negative association between PFA resistance and zidovudine resistance.



Browser Board

 Co-occurred Entities




   Filtrator